US SB516 | 2019-2020 | 116th Congress

Status

Spectrum: Bipartisan Bill
Status: Introduced on February 14 2019 - 25% progression, died in committee
Action: 2019-02-14 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours.The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Prescription Drug Monitoring Act of 2019

Sponsors


History

DateChamberAction
2019-02-14SenateRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Same As/Similar To

HB3974 (Same As) 2019-07-26 - Referred to the Subcommittee on Health.

Subjects


US Congress State Sources


Bill Comments

feedback